Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer
Journal of Korean Medical Science
;
: 598-603, 2008.
Article
in English
| WPRIM
| ID: wpr-9481
ABSTRACT
The authors designed this study to determine the clinical effectiveness of trimodality treatment, i.e., transurethral resection of a bladder tumor (TURBT) and concurrent chemoradiotherapy (CRT). Twenty patients with a muscle-invasive bladder cancer were treated by TURBT followed by concurrent cisplatin (75 mg/m(2) day), administered on weeks 1 and 4 of radiotherapy. According to residual tumor status after TURBT, patients were classified into patients with a complete TURBT group and incomplete TURBT group. Response to treatment was evaluated by restaging TURBT at 4 weeks after completing CRT (post-CRT). Fifteen patients (75%) achieved complete remission (CR) at restaging; 10 patients (50%) remained continuously free of tumor recurrence. Disease-specific and overall survivals were 51.1% and 38.6% at 5 yr post-CRT, respectively. Of 16 patients in the complete TURBT group, 14 patients (87.5%) achieved CR, which was significantly different from that observed in the incomplete TURBT group, in which only 1 (25%) of 4 patients achieved CR (p=0.032). Five- year disease-specific and overall survivals were 71.6% and 53.5%, respectively. Ten patients (90.9%) maintained their own bladder among the 11 surviving patients. Trimodality treatment was found to be an effective treatment in patients who underwent complete TURBT for a muscle-invasive bladder cancer.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Urinary Bladder Neoplasms
/
Cisplatin
/
Salvage Therapy
/
Combined Modality Therapy
/
Muscle Neoplasms
/
Neoplasm Invasiveness
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS